Kadimastem Ltd (KMSTF) Stock Analysis
DELISTED 2025
What happened to Kadimastem Ltd (KMSTF) stock?
Kadimastem Ltd (KMSTF) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kadimastem Ltd (KMSTF) trades at $3.21. Kadimastem Ltd (KMSTF) is an Israeli biopharmaceutical company specializing in regenerative medicine therapies aimed at neurodegenerative disorders. Market cap: $9.50M, Sector: Healthcare.
Last analyzed: Jun 14, 2026Analyst Coverage for KMSTF: KMSTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KMSTF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
KMSTF: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Kadimastem Ltd (KMSTF) Healthcare & Pipeline Overview
Kadimastem Ltd (KMSTF) is a pioneering Israeli biopharmaceutical company focused on developing innovative regenerative medicine therapies, particularly for neurodegenerative disorders, leveraging human embryonic stem cells to address critical healthcare challenges.
What Is the Investment Thesis for KMSTF?
Kadimastem Ltd (KMSTF) presents a unique investment thesis driven by its innovative approach to regenerative medicine and a strong clinical pipeline. The company's lead product, AstroRx, is currently in Phase 1/2a trials, with significant potential to address the growing prevalence of neurodegenerative disorders, particularly ALS. The global market for ALS treatments is projected to grow significantly, driven by increasing awareness and demand for effective therapies. Additionally, the development of IsletRx for diabetes treatment further diversifies Kadimastem's pipeline, tapping into a market that is experiencing rapid growth due to rising diabetes prevalence. As the company progresses through clinical trials, successful outcomes could lead to strategic partnerships or acquisitions, enhancing its market position and financial performance. However, investors should be aware of the inherent risks associated with clinical trials, including regulatory hurdles and funding challenges. Overall, Kadimastem's focus on innovative therapies, coupled with a robust pipeline, positions it well for future growth in the biotechnology sector.
Based on FMP financials and quantitative analysis
KMSTF Key Highlights
Market Cap of $9.50M reflects the company's position in the biotechnology sector.
- Phase 1/2a clinical trials for AstroRx targeting ALS indicate potential for significant market impact.
- Development of IsletRx for diabetes treatment diversifies the product pipeline.
- Beta of 0.57 suggests lower volatility compared to the broader market.
- No dividend yield indicates a focus on reinvestment into research and development.
Who Are KMSTF's Competitors?
KMSTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVXL Anavex Life Sciences Corp. | $3.13 | -7.67% | $290M | 51 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| SGMO Sangamo Therapeutics, Inc. | $0.07 | +0.00% | $30.7M | — |
| TGTX TG Therapeutics, Inc. | $50.56 | -2.19% | $7.74B | 65 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KMSTF's Key Strengths?
Innovative approach to regenerative medicine with a focus on stem cell therapies.
- Strong clinical pipeline addressing significant healthcare needs.
- Agile structure allows for rapid decision-making and adaptation.
- Established partnerships with research institutions and industry leaders.
What Are KMSTF's Weaknesses?
Limited financial resources as a small OTC-listed company.
- Dependence on successful clinical trial outcomes for future growth.
- Market perception risks associated with being a smaller biotech firm.
- Lack of diversified product offerings compared to larger competitors.
What Could Drive KMSTF Stock Higher?
Results from Phase 1/2a clinical trials for AstroRx expected in the next 12 months.
- Development of IsletRx for diabetes treatment progressing through preclinical stages.
- Exploration of strategic partnerships to enhance funding and clinical resources.
- Potential announcements regarding additional clinical trials or product developments.
- Continuous monitoring of regulatory changes impacting the biotechnology sector.
What Are the Key Risks for KMSTF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles could delay clinical trial approvals and product launches.
- Market volatility affecting investor sentiment and funding availability.
- Competition from larger biotech firms may impact market share.
- Clinical trial outcomes may not meet expectations, affecting future growth.
What Are the Growth Opportunities for KMSTF?
- Expansion of AstroRx Trials: Kadimastem's ongoing Phase 1/2a clinical trials for AstroRx represent a significant growth opportunity. Successful trial results could lead to accelerated regulatory approval and market entry, addressing a critical need in ALS treatment. The global ALS market is projected to reach $7 billion by 2028, providing a substantial revenue opportunity for Kadimastem.
- With rising diabetes prevalence, effective therapies are in high demand, and Kadimastem's innovative approach could capture a significant market share.
- Strategic Partnerships: Kadimastem has the potential to form strategic partnerships with larger pharmaceutical companies, which could provide funding and resources for clinical development. Collaborations could enhance the company's credibility and accelerate the commercialization of its therapies, creating additional revenue streams.
- Geographic Expansion: As Kadimastem continues to develop its therapies, expanding its presence into international markets could drive growth. Targeting regions with high unmet medical needs for neurodegenerative and diabetic treatments can increase the company's market reach and revenue potential.
- Technological Advancements: Continued investment in research and development may lead to technological breakthroughs in regenerative medicine. By leveraging its proprietary technology platform, Kadimastem can enhance its product offerings and improve patient outcomes, positioning itself as a leader in the biotechnology sector.
What Threats Does KMSTF Face?
- Intense competition from larger biotech and pharmaceutical companies.
- Regulatory hurdles and potential delays in clinical trial approvals.
- Market volatility and funding challenges for small-cap biotech firms.
- Rapidly changing healthcare policies impacting reimbursement and access.
What Are KMSTF's Competitive Advantages?
- Proprietary technology platform for developing cell-based therapies.
- Focus on high unmet medical needs in neurodegenerative and diabetic conditions.
- Strong intellectual property portfolio protecting innovative therapies.
- Agility as a small company allows for rapid adaptation to market changes.
- Established clinical partnerships enhance credibility and research capabilities.
What Does KMSTF Do?
Founded in 2008, Kadimastem Ltd is an Israeli biopharmaceutical company headquartered in Ness Ziona, Israel. The company is dedicated to the development of regenerative medicine therapies that utilize human embryonic stem cells, primarily targeting neurodegenerative disorders. Kadimastem's flagship product, AstroRx, is a clinical-grade human astrocyte therapy currently in Phase 1/2a clinical trials for treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. This innovative approach aims to restore cellular function and promote recovery in patients suffering from debilitating neurological diseases. In addition to AstroRx, Kadimastem is also developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes, highlighting the company's commitment to addressing a range of serious health issues. Over the years, Kadimastem has established a robust pipeline of therapies that leverage its proprietary technology platform, positioning itself as a key player in the regenerative medicine sector. With a small team of 11 employees, the company is agile and focused on advancing its clinical trials and expanding its therapeutic offerings. Kadimastem's focus on cutting-edge research and development, combined with its strategic partnerships, enables it to remain at the forefront of the biotechnology industry, addressing unmet medical needs and improving patient outcomes.
What Products and Services Does KMSTF Offer?
- Develops regenerative medicine therapies using human embryonic stem cells.
- Focuses on treatments for neurodegenerative disorders, particularly ALS.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Explores innovative solutions for diabetes treatment through IsletRx.
- Maintains a small, agile team for focused research and development.
- Collaborates with academic and industry partners to advance its clinical pipeline.
How Does KMSTF Make Money?
- Generates revenue through the development and commercialization of innovative therapies.
- Secures funding through partnerships, grants, and potential collaborations.
- Focuses on clinical trial advancements to attract investor interest and support.
- Utilizes a small team to maintain low operational costs while maximizing R&D efforts.
- Aims for strategic licensing agreements with larger pharmaceutical companies.
What Industry Does KMSTF Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the field of regenerative medicine. With an increasing global emphasis on personalized medicine and cell-based therapies, companies like Kadimastem Ltd are well-positioned to capitalize on emerging trends. The market for neurodegenerative disorder treatments is expanding, driven by an aging population and rising incidence rates. As the demand for effective therapies grows, Kadimastem's focus on innovative solutions places it in a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms. The global regenerative medicine market is expected to reach approximately $40 billion by 2026, highlighting the potential for significant growth in this sector.
Who Are KMSTF's Key Customers?
- Patients suffering from neurodegenerative disorders such as ALS.
- Healthcare providers seeking advanced treatment options for diabetes.
- Research institutions interested in regenerative medicine technologies.
- Pharmaceutical companies looking for innovative therapy partnerships.
- Investors interested in biotechnology and regenerative medicine sectors.
Financial Health
Kadimastem Ltd's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
KMSTF Valuation & Market Position
With a $9.50M market cap, Kadimastem Ltd sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Kadimastem Ltd stands at 0.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -42.5%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Kadimastem Ltd operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ness Ziona, IL. The company is led by CEO Ronen Twito. KMSTF has traded publicly since 2021.
KMSTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative approach to regenerative medicine with a focus on stem cell therapies.
- Strong clinical pipeline addressing significant healthcare needs.
- Agile structure allows for rapid decision-making and adaptation.
- Established partnerships with research institutions and industry leaders.
Bear Case
- Limited financial resources as a small OTC-listed company.
- Dependence on successful clinical trial outcomes for future growth.
- Market perception risks associated with being a smaller biotech firm.
- Lack of diversified product offerings compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KMSTF Latest News
No recent news available for KMSTF.
Leadership: Ronen Twito
CEO
Ronen Twito has extensive experience in the biotechnology sector, having held various leadership roles in both public and private companies. He has a strong background in business development and strategic planning, with a focus on advancing innovative therapies. Twito holds a degree in Life Sciences and has contributed significantly to the growth and development of Kadimastem since its inception.
Track Record: Under Ronen Twito's leadership, Kadimastem has successfully advanced its clinical pipeline, particularly with the development of AstroRx. He has been instrumental in establishing key partnerships and securing funding to support the company's research initiatives.
KMSTF OTC Market Information
The OTC Other tier includes companies that do not meet the higher listing standards of major exchanges like NYSE or NASDAQ. These companies may have less stringent reporting requirements, which can affect transparency and investor confidence.
- OTC Tier: OTC Other
- Limited financial resources and reliance on external funding.
- Potential for low trading volume and liquidity challenges.
- Regulatory risks associated with clinical trials and product approvals.
- Market perception risks due to the company's smaller size and OTC status.
- Review recent clinical trial results and updates.
- Examine financial statements and funding sources.
- Assess the competitive landscape and market positioning.
- Investigate partnerships and collaborations in place.
- Monitor regulatory developments affecting the biotechnology sector.
- Established clinical trial partnerships with reputable institutions.
- Transparent communication of clinical trial progress and results.
- Presence of experienced leadership with a strong track record in biotech.
Kadimastem Ltd Healthcare Stock: Key Questions Answered
What happened to Kadimastem Ltd (KMSTF) stock?
Kadimastem Ltd (KMSTF) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
Can I still buy KMSTF shares?
No. KMSTF stopped trading on public markets in October 2025, so the shares are not available through a broker. Anything you see quoted for KMSTF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before KMSTF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Kadimastem Ltd. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Kadimastem Ltd do?
Kadimastem Ltd is focused on developing innovative regenerative medicine therapies using human embryonic stem cells. The company primarily targets neurodegenerative disorders, with its lead product, AstroRx, currently in clinical trials for ALS. Additionally, Kadimastem is working on IsletRx, a therapy aimed at treating diabetes, showcasing its commitment to addressing significant healthcare challenges.
What are the key growth opportunities for KMSTF in healthcare?
Kadimastem Ltd has several growth opportunities, including the expansion of its clinical trials for AstroRx, which targets the growing ALS market projected to reach $7 billion by 2028. Strategic partnerships and geographic expansion further enhance its growth potential.
What are the main risks for KMSTF?
Kadimastem Ltd faces several risks, including regulatory hurdles that may delay clinical trial approvals and product launches. As a smaller OTC-listed company, it is also susceptible to market volatility, which can affect investor sentiment and funding availability. Additionally, competition from larger biotech firms poses a threat to market share, and clinical trial outcomes may not always meet expectations, impacting future growth prospects.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information as of June 2026; future developments may alter company performance and market conditions.